The "little pink pill" is now available to even more women. The Food and Drug Administration (FDA) just approved Addyi for postmenopausal women, which makes this the first medication for low sexual ...

In a 10-year study of postmenopausal women, tea consumption shows a small but significant benefit for bone mineral density, ...

The once-a-day treatment, which acts on brain chemicals that affect mood and appetite, had initially been OK’d for ...

HSDD affects 40%-55% of postmenopausal women, often due to hormonal changes, impacting sexual desire and quality of life.

While the expanded approval fulfills an unmet meet in postmenopausal women, its benefits are marginal in that population.

The FDA approved Addyi (flibanserin), a libido-enhancing drug, in postmenopausal women under the age of 65. Experts explain ...

The FDA has expanded the approval of Addyi to include the treatment of hypoactive sexual desire disorder in women less than 65 years.

New AIIMS research reveals a critical immune link between gut bacteria and bone loss in postmenopausal women. Oestrogen ...

As you’ve gotten older, you’ve probably noticed your body changing. Maybe you feel the effects of a glass of wine more than you used to or that you gain weight easier than before. Maybe you’re ...

Many doctors agree with the Food and Drug Administration’s recent decision to remove the black box warnings on at least some ...

With Monday's ruling, Addyi becomes the first and only FDA-approved pill for low sexual desire in postmenopausal women-an ...